George Siber

George Siber previously served as Executive Vice President and Chief Scientific Officer at Wyeth Vaccines, where he oversaw the development and launch of a number of widely distributed vaccines, including Prevnar (pneumococcal), Meningitec (meningococcal C conjugate vaccine), and FluMist (a live nasal influenza vaccine co-developed with MedImmune). Prior to Wyeth, he directed the Massachusetts Biologic Laboratories and was an associate professor at Harvard Medical School and Dana-Farber Cancer Institute. Dr. Siber’s vast vaccine experience includes serving on numerous governmental and international committees, including at the World Health Organization, the International Vaccine Institute, the European Commission’s ADITEC Vaccine Consortium, and the National Institutes of Health. He currently serves as Chief Scientific Officer of ClearPath Vaccines Company and also as director and/or scientific advisor to a number of other companies focused on developing vaccines and therapeutics for infectious diseases, including Genocea Biosciences, Selecta Biosciences, Vedantra Pharmaceuticals, and Visterra.